INTRODUCTION: Primary open-angle glaucoma (POAG) is a leading cause of visual impairment worldwide and a complex genetic disorder that affects mostly adults. Mutations in the MYOCILIN (MYOC) and OPTINEURIN genes account for rare forms with a Mendelian inheritance and for <5% of all POAG cases. The CYP1B1 gene, a member of the cytochrome P450 gene family, is a major cause of primary congenital glaucoma (PCG), a rare and severely blinding disease with recessive inheritance. However, CYP1B1 mutations have also been associated with cases of juvenile-onset glaucoma in some PCG families or shown to modify the age of onset of glaucoma linked to a MYOC mutation in a large family. OBJECTIVE: To investigate the role of CYP1B1 mutations in POAG predisposition, irrespective of the presence of a MYOC mutation. METHODS AND SUBJECTS: CYP1B1 coding region variation was characterised by denaturing high performance liquid chromatography (DHPLC) and sequencing in 236 unrelated French Caucasian POAG patients and 47 population-matched controls. RESULTS: Eleven (4.6%) patients carried one or two mutated CYP1B1 gene(s) and no MYOC mutation. They showed juvenile or middle-age onset of disease (median age at diagnosis, 40 years, range 13-52), significantly earlier than in non-carrier patients. Apart from one, all mutations detected in POAG patients were previously associated with PCG. CONCLUSION: CYP1B1 mutations might pose a significant risk for early-onset POAG and might also modify glaucoma phenotype in patients who do not carry a MYOC mutation.
INTRODUCTION:Primary open-angle glaucoma (POAG) is a leading cause of visual impairment worldwide and a complex genetic disorder that affects mostly adults. Mutations in the MYOCILIN (MYOC) and OPTINEURIN genes account for rare forms with a Mendelian inheritance and for <5% of all POAG cases. The CYP1B1 gene, a member of the cytochrome P450 gene family, is a major cause of primary congenital glaucoma (PCG), a rare and severely blinding disease with recessive inheritance. However, CYP1B1 mutations have also been associated with cases of juvenile-onset glaucoma in some PCG families or shown to modify the age of onset of glaucoma linked to a MYOC mutation in a large family. OBJECTIVE: To investigate the role of CYP1B1 mutations in POAG predisposition, irrespective of the presence of a MYOC mutation. METHODS AND SUBJECTS:CYP1B1 coding region variation was characterised by denaturing high performance liquid chromatography (DHPLC) and sequencing in 236 unrelated French Caucasian POAG patients and 47 population-matched controls. RESULTS: Eleven (4.6%) patients carried one or two mutated CYP1B1 gene(s) and no MYOC mutation. They showed juvenile or middle-age onset of disease (median age at diagnosis, 40 years, range 13-52), significantly earlier than in non-carrier patients. Apart from one, all mutations detected in POAG patients were previously associated with PCG. CONCLUSION:CYP1B1 mutations might pose a significant risk for early-onset POAG and might also modify glaucoma phenotype in patients who do not carry a MYOC mutation.
Authors: B A Bejjani; D W Stockton; R A Lewis; K F Tomey; D K Dueker; M Jabak; W F Astle; J R Lupski Journal: Hum Mol Genet Date: 2000-02-12 Impact factor: 6.150
Authors: J T Buters; S Sakai; T Richter; T Pineau; D L Alexander; U Savas; J Doehmer; J M Ward; C R Jefcoate; F J Gonzalez Journal: Proc Natl Acad Sci U S A Date: 1999-03-02 Impact factor: 11.205
Authors: J H Fingert; E Héon; J M Liebmann; T Yamamoto; J E Craig; J Rait; K Kawase; S T Hoh; Y M Buys; J Dickinson; R R Hockey; D Williams-Lyn; G Trope; Y Kitazawa; R Ritch; D A Mackey; W L Alward; V C Sheffield; E M Stone Journal: Hum Mol Genet Date: 1999-05 Impact factor: 6.150
Authors: Y Mashima; Y Suzuki; Y Sergeev; Y Ohtake; T Tanino; I Kimura; H Miyata; M Aihara; H Tanihara; M Inatani; N Azuma; T Iwata; M Araie Journal: Invest Ophthalmol Vis Sci Date: 2001-09 Impact factor: 4.799
Authors: I Stoilov; A N Akarsu; I Alozie; A Child; M Barsoum-Homsy; M E Turacli; M Or; R A Lewis; N Ozdemir; G Brice; S G Aktan; L Chevrette; M Coca-Prados; M Sarfarazi Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: M Sarfarazi; A N Akarsu; A Hossain; M E Turacli; S G Aktan; M Barsoum-Homsy; L Chevrette; B S Sayli Journal: Genomics Date: 1995-11-20 Impact factor: 5.736
Authors: Linda M Reis; Rebecca C Tyler; Roberto Zori; Jennifer Burgess; Jennifer Mueller; Elena V Semina Journal: Ophthalmic Genet Date: 2013-09-11 Impact factor: 1.803
Authors: Fereshteh Chitsazian; Betsabeh Khoramian Tusi; Elahe Elahi; Heidar Amini Saroei; Mohammad H Sanati; Shahin Yazdani; Mohammad Pakravan; Navid Nilforooshan; Yadollah Eslami; Mohammad Ali Zare Mehrjerdi; Reza Zareei; Mahmood Jabbarvand; Ali Abdolahi; Ali R Lasheyee; Arash Etemadi; Behnaz Bayat; Mehdi Sadeghi; Mohammad M Banoei; Behnam Ghafarzadeh; Mohammad R Rohani; Akram Rismanchian; Yvonne Thorstenson; Mansoor Sarfarazi Journal: J Mol Diagn Date: 2007-07 Impact factor: 5.568
Authors: Kate E Keller; Yong-Feng Yang; Ying Ying Sun; Renee Sykes; Natalie Donna Gaudette; John R Samples; Ted S Acott; Mary K Wirtz Journal: J Ocul Pharmacol Ther Date: 2014-01-23 Impact factor: 2.671
Authors: M Kamio; A Meguro; M Ota; N Nomura; K Kashiwagi; F Mabuchi; H Iijima; K Kawase; T Yamamoto; M Nakamura; A Negi; T Sagara; T Nishida; M Inatani; H Tanihara; M Aihara; M Araie; T Fukuchi; H Abe; T Higashide; K Sugiyama; T Kanamoto; Y Kiuchi; A Iwase; S Ohno; H Inoko; N Mizuki Journal: Clin Ophthalmol Date: 2009-06-02